Who Paid My Doc
Mohamed El-Gabalawy
Psychiatry Pasadena, CA Medical Doctor
NPI 1407967631 CMS profile 64114
1111 S Arroyo Pkwy, Suite 405, Pasadena, CA 91105
General payments
$3,358
Research payments
$121
Ownership & investment interest
$0
Research they led as principal investigator
$1,871,202
Through program year 2025, Mohamed El-Gabalawy of Pasadena, CA is reported in the CMS Open Payments database as having received $3,358 across 30 general payments and $121 in research payments paid to them. Separately, studies naming them as principal investigator received $1,871,202 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 85th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,794 | 22 | |
| 2023 | Research | $121 | 3 | |
| 2021 | General | $122 | 1 | |
| 2020 | General | $171 | 3 | |
| 2019 | General | $271 | 4 |
Beside peers
- Mohamed El-Gabalawy
- Psychiatry median
- Middle half of Psychiatry
- National median
In program year 2025, general payments to Mohamed El-Gabalawy were reported at $2,794. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.
Show as a table
| Year | Mohamed El-Gabalawy | Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $271 | $184 | $59–$605 | $163 |
| 2020 | $171 | $119 | $36–$372 | $114 |
| 2021 | $122 | $143 | $43–$576 | $132 |
| 2022 | $0 | $153 | $50–$590 | $149 |
| 2023 | $0 | $170 | $56–$651 | $160 |
| 2024 | $0 | $179 | $57–$673 | $164 |
| 2025 | $2,794 | $180 | $58–$685 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 4 billing codesPaid by Medicare
$22,840
Medicare patients
90
Services billed
249
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Depression | 63% | |
| Alzheimer's or dementia | 61% | |
| Arthritis | 58% | |
| Ischemic heart disease | 48% | |
| Atrial fibrillation | 44% | |
| Chronic kidney disease | 40% | |
| Heart failure | 37% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
33 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Psychiatry in California
Related records
Psychiatry in California
Practitioners in the same specialty and state, ranked by reported value.
All Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.